These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 19104515)

  • 1. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
    Kirn DH; Thorne SH
    Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Oncolytic Poxviruses: An Emerging Paradigm in Cancer Therapy.
    Chakraborty P; Kumar R; Karn S; Raviya DD; Mondal P
    Adv Exp Med Biol; 2024; 1451():369-381. PubMed ID: 38801591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replicating poxviruses for human cancer therapy.
    Kim M
    J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic potential of oncolytic vaccinia virus.
    Thorne SH
    Immunol Res; 2011 Aug; 50(2-3):286-93. PubMed ID: 21717084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
    Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
    Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
    Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
    Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
    Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
    Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH
    J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
    Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
    Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.
    Evgin L; Vähä-Koskela M; Rintoul J; Falls T; Le Boeuf F; Barrett JW; Bell JC; Stanford MM
    Mol Ther; 2010 May; 18(5):896-902. PubMed ID: 20160706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of
    Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
    EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
    Al Yaghchi C; Zhang Z; Alusi G; Lemoine NR; Wang Y
    Immunotherapy; 2015; 7(12):1249-58. PubMed ID: 26595180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
    Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virotherapy--cancer targeted pharmacology.
    Tedcastle A; Cawood R; Di Y; Fisher KD; Seymour LW
    Drug Discov Today; 2012 Mar; 17(5-6):215-20. PubMed ID: 22198165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
    Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
    Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.